AstraZeneca Collaborates with U. of Cambridge, Cancer Research UK on Cancer Projects | GenomeWeb

NEW YORK (GenomeWeb News) – AstraZeneca announced today announced a two-year collaboration with the University of Cambridge and Cancer Research UK on three preclinical and clinical oncology projects, including one focused on gaining a better understanding of the genetic makeup of a patient's cancer through their tumor DNA.

Overall, the collaboration aims to move cancer research forward by studying tumor mutations and new investigational therapies in prostate, pancreatic, and possibly other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.